Ray-Coquard I, Pautier P, Pignata S, et al. - In this randomized, double-blind, international phase 3 trial of individuals who had newly diagnosed, advanced, high-grade ovarian cancer and were having a response following first-line platinum–taxane chemotherapy plus bevacizumab, experts determined the impact of combining maintenance olaparib and bevacizumab in women with newly diagnosed advanced ovarian cancer with a BRCA mutation, irrespective of BRCA mutation status. A total of 806 people who underwent randomization, 537 were assigned to receive olaparib and 269 to receive a placebo. In individuals with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, adding maintenance olaparib gave a notable progression-free survival advantage, which was substantial in people with HRD-positive tumors, including those without a BRCA mutation.